Grzegorz Kasparek
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Grzegorz Kasparek has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Adrianna Szczecińska
University Clinical Hospital in Poznan, 49 Przybyszewskiego Street, 60-355 Poznan, Poland
8 shared publications - Aleksandra Mliczek
University Clinical Hospital in Poznan, 49 Przybyszewskiego Street, 60-355 Poznan, Poland
8 shared publications - Hubert Kulawinek
University Clinical Hospital in Poznan, 49 Przybyszewskiego Street, 60-355 Poznan, Poland
8 shared publications - Jakub Maksymilian Bajer
Poznan University of Medical Sciences, Student Scientific Society, Poznan, Poland
8 shared publications - Julia Obersztyn
University Clinical Hospital in Poznan, 49 Przybyszewskiego Street, 60-355 Poznan, Poland
8 shared publications - Krzysztof Maksym Kasparek
Poznań University of Medical Sciences, Poland
8 shared publications
Latest Publications
- Open Access
- 29 September 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 5 (3(51))
CIGARETTE SMOKING AS A RISK FACTOR FOR IMPAIRED POSTOPERATIVE WOUND HEALING PROCESS
Background. Proper postoperative wound healing is an essential and ongoing component of effective hospital care. Cigarette smoking might be one of the modifiable risk factors for impaired wound healing, which can lead to prolonged hospitalization and increased healthcare costs. Objective. This systematic review examined existing literature on the documented impact of cigarette smoking on the incidence and types of postoperative wound-healing complications by comparing smokers with non-smokers and whether preoperative smoking cessation significantly reduces the risk of these complications. Methods. A structured literature review was conducted using PubMed, Elsevier, ScienceDirect and Scopus were searched between June and August 2026. Studies included systematic reviews, meta-analyses, cohort studies, and review articles published between 2000 and 2025 Results. Smoking cigarettes disrupts the functioning of our body and is associated with numerous disorders and impairs postoperative wound healing. Importantly, these adverse outcomes may be reduced through effective smoking cessation interventions. Conclusion. Smoking cessation before surgery is an important strategy for reducing postoperative complications, healthcare costs, and mortality. Preferably, smoking should be stopped at least 4–6 weeks before elective surgery and continued for 4–8 weeks postoperatively to maximize the potential benefits. Overall, quitting smoking improves surgical outcomes and can be lifesaving.
- 29 September 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 5 (3(51))
Open AccessCIGARETTE SMOKING AS A RISK FACTOR FOR IMPAIRED POSTOPERATIVE WOUND HEALING PROCESS
Background. Proper postoperative wound healing is an essential and ongoing component of effective hospital care. Cigarette smoking might be one of the modifiable risk factors for impaired wound healing, which can lead to prolonged hospitalization and increased healthcare costs. Objective. This systematic review examined existing literature on the documented impact of cigarette smoking on the incidence and types of postoperative wound-healing complications by comparing smokers with non-smokers and whether preoperative smoking cessation significantly reduces the risk of these complications. Methods. A structured literature review was conducted using PubMed, Elsevier, ScienceDirect and Scopus were searched between June and August 2026. Studies included systematic reviews, meta-analyses, cohort studies, and review articles published between 2000 and 2025 Results. Smoking cigarettes disrupts the functioning of our body and is associated with numerous disorders and impairs postoperative wound healing. Importantly, these adverse outcomes may be reduced through effective smoking cessation interventions. Conclusion. Smoking cessation before surgery is an important strategy for reducing postoperative complications, healthcare costs, and mortality. Preferably, smoking should be stopped at least 4–6 weeks before elective surgery and continued for 4–8 weeks postoperatively to maximize the potential benefits. Overall, quitting smoking improves surgical outcomes and can be lifesaving.
- Open Access
- 29 September 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 5 (3(51))
ERYSIPELAS AS AN ACUTE STREPTOCOCCAL SKIN INFECTION: A LITERATURE REVIEW
Erysipelas is an acute bacterial infection of the upper dermis and superficial lymphatic vessels. Beta hemolytic streptococci cause most typical cases. The disease often starts suddenly with painful erythema, warmth, swelling, fever, chills, and a raised or sharply demarcated skin border. Most patients respond to antibiotic therapy, but recurrent episodes can damage lymphatic drainage and create chronic edema. This narrative review summarizes current evidence on etiology, risk factors, clinical variants, diagnosis, treatment, complications, prevention, and care organization. It gives special attention to recurrent lower limb disease, because recurrence links infection with mobility loss, work absence, repeated antibiotic exposure, compression therapy, community nursing, and social support. The review also distinguishes infectious erysipelas from carcinoma erysipeloides, a malignant mimic that can delay cancer diagnosis when clinicians treat persistent erythema as infection.
- 29 September 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 5 (3(51))
Open AccessERYSIPELAS AS AN ACUTE STREPTOCOCCAL SKIN INFECTION: A LITERATURE REVIEW
Erysipelas is an acute bacterial infection of the upper dermis and superficial lymphatic vessels. Beta hemolytic streptococci cause most typical cases. The disease often starts suddenly with painful erythema, warmth, swelling, fever, chills, and a raised or sharply demarcated skin border. Most patients respond to antibiotic therapy, but recurrent episodes can damage lymphatic drainage and create chronic edema. This narrative review summarizes current evidence on etiology, risk factors, clinical variants, diagnosis, treatment, complications, prevention, and care organization. It gives special attention to recurrent lower limb disease, because recurrence links infection with mobility loss, work absence, repeated antibiotic exposure, compression therapy, community nursing, and social support. The review also distinguishes infectious erysipelas from carcinoma erysipeloides, a malignant mimic that can delay cancer diagnosis when clinicians treat persistent erythema as infection.
- Open Access
- 29 September 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 5 (3(51))
ARTIFICIAL INTELLIGENCE FOR PREDICTING CHRONIC KIDNEY DISEASE PROGRESSION: A REVIEW OF CURRENT EVIDENCE AND GLOBAL CLINICAL IMPLICATIONS
Chronic Kidney Disease (CKD) affects approximately 800 million people globally and represents a growing public health and economic burden. Traditional prognostic tools, such as the Kidney Failure Risk Equation, demonstrate limited discriminative accuracy in early disease stages (G1–G3), where kidney failure events are inherently rare. Aim: The primary objective of this review is to evaluate the performance of artificial intelligence (AI) and machine learning (ML) models in predicting CKD progression. Methods: A narrative review approach was used to synthesise evidence published between January 2022 and June 2026, identified through searches of PubMed/MEDLINE, Embase, and Web of Science. Ten studies comprising diverse international cohorts were included. Key findings: AI/ML models demonstrated superior predictive accuracy compared with traditional benchmarks, achieving a pooled Area Under the Curve (AUC) of 0.87–0.89. Long Short-Term Memory recurrent neural networks, leveraging longitudinal electronic health record data, attained AUROC scores of 0.957–0.967. Tree-based ensemble methods, including Random Forest and XGBoost, showed robust performance across heterogeneous populations. However, a consistent imbalance between high model specificity (0.87–0.92) and relatively low sensitivity (0.43–0.68) was identified, primarily attributable to class imbalance in training datasets. Explainable AI frameworks, particularly SHAP and LIME, successfully addressed the interpretability barrier, identifying eGFR slope, proteinuria, and haemoglobin as dominant predictors of renal decline. Conclusions: These findings support a transition toward proactive, precision-based nephrology. Global clinical adoption, however, requires standardisation of predictor criteria, optimisation of model sensitivity, broader external validation across diverse ethnic populations, and targeted solutions for implementation in low- and middle-income healthcare settings.
- 29 September 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 5 (3(51))
Open AccessARTIFICIAL INTELLIGENCE FOR PREDICTING CHRONIC KIDNEY DISEASE PROGRESSION: A REVIEW OF CURRENT EVIDENCE AND GLOBAL CLINICAL IMPLICATIONS
Chronic Kidney Disease (CKD) affects approximately 800 million people globally and represents a growing public health and economic burden. Traditional prognostic tools, such as the Kidney Failure Risk Equation, demonstrate limited discriminative accuracy in early disease stages (G1–G3), where kidney failure events are inherently rare. Aim: The primary objective of this review is to evaluate the performance of artificial intelligence (AI) and machine learning (ML) models in predicting CKD progression. Methods: A narrative review approach was used to synthesise evidence published between January 2022 and June 2026, identified through searches of PubMed/MEDLINE, Embase, and Web of Science. Ten studies comprising diverse international cohorts were included. Key findings: AI/ML models demonstrated superior predictive accuracy compared with traditional benchmarks, achieving a pooled Area Under the Curve (AUC) of 0.87–0.89. Long Short-Term Memory recurrent neural networks, leveraging longitudinal electronic health record data, attained AUROC scores of 0.957–0.967. Tree-based ensemble methods, including Random Forest and XGBoost, showed robust performance across heterogeneous populations. However, a consistent imbalance between high model specificity (0.87–0.92) and relatively low sensitivity (0.43–0.68) was identified, primarily attributable to class imbalance in training datasets. Explainable AI frameworks, particularly SHAP and LIME, successfully addressed the interpretability barrier, identifying eGFR slope, proteinuria, and haemoglobin as dominant predictors of renal decline. Conclusions: These findings support a transition toward proactive, precision-based nephrology. Global clinical adoption, however, requires standardisation of predictor criteria, optimisation of model sensitivity, broader external validation across diverse ethnic populations, and targeted solutions for implementation in low- and middle-income healthcare settings.
- Open Access
- 28 September 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 5 (3(51))
ATTENTION-DEFICIT/HYPERACTIVITY DISORDER AND PSYCHIATRIC COMORBIDITY: A REVIEW OF CURRENT EVIDENCE
Background: Attention-deficit/hyperactivity disorder (ADHD) is a common neurodevelopmental disorder that frequently persists into adulthood and is associated with substantial psychiatric comorbidity. Co-occurring mental disorders may complicate diagnosis, worsen functional impairment, and negatively affect treatment outcomes. Objective: This review aimed to summarize and critically analyze current evidence regarding the coexistence of ADHD and other psychiatric disorders in adults, with particular emphasis on depressive disorders, anxiety disorders, bipolar disorder, substance use disorders, sleep disorders, and autism spectrum disorder. Methods: A comprehensive literature search was conducted using PubMed, the NCBI database, and peer-reviewed biomedical journals. Publications from database inception through July 2025 were considered, with particular emphasis on studies published during the preceding ten years. Systematic reviews, meta-analyses, population-based studies, and longitudinal cohorts were prioritized. The review focused on the prevalence, clinical characteristics, potential shared mechanisms, prognostic implications, and treatment considerations associated with psychiatric comorbidity in adult ADHD. Results: Psychiatric comorbidity was identified as a frequent characteristic of adult ADHD, with approximately 60–80% of adults experiencing at least one additional psychiatric disorder during their lifetime. Depressive and anxiety disorders were among the most prevalent comorbidities and were associated with greater functional impairment and reduced quality of life. Bipolar disorder presented important diagnostic challenges due to overlapping symptoms, while substance use disorders were associated with poorer psychosocial outcomes and increased treatment complexity. Sleep disorders were highly prevalent and appeared to interact bidirectionally with ADHD symptoms. The frequent co-occurrence of ADHD and autism spectrum disorder further supports shared neurodevelopmental mechanisms. Emotional dysregulation and executive dysfunction emerged as potential transdiagnostic factors contributing to psychiatric vulnerability. Conclusions: Adult ADHD should be considered a complex, multidimensional disorder that rarely occurs in isolation. Comprehensive assessment of psychiatric comorbidity and integrated, individualized treatment are essential to improve clinical outcomes and quality of life.
- 28 September 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 5 (3(51))
Open AccessATTENTION-DEFICIT/HYPERACTIVITY DISORDER AND PSYCHIATRIC COMORBIDITY: A REVIEW OF CURRENT EVIDENCE
Background: Attention-deficit/hyperactivity disorder (ADHD) is a common neurodevelopmental disorder that frequently persists into adulthood and is associated with substantial psychiatric comorbidity. Co-occurring mental disorders may complicate diagnosis, worsen functional impairment, and negatively affect treatment outcomes. Objective: This review aimed to summarize and critically analyze current evidence regarding the coexistence of ADHD and other psychiatric disorders in adults, with particular emphasis on depressive disorders, anxiety disorders, bipolar disorder, substance use disorders, sleep disorders, and autism spectrum disorder. Methods: A comprehensive literature search was conducted using PubMed, the NCBI database, and peer-reviewed biomedical journals. Publications from database inception through July 2025 were considered, with particular emphasis on studies published during the preceding ten years. Systematic reviews, meta-analyses, population-based studies, and longitudinal cohorts were prioritized. The review focused on the prevalence, clinical characteristics, potential shared mechanisms, prognostic implications, and treatment considerations associated with psychiatric comorbidity in adult ADHD. Results: Psychiatric comorbidity was identified as a frequent characteristic of adult ADHD, with approximately 60–80% of adults experiencing at least one additional psychiatric disorder during their lifetime. Depressive and anxiety disorders were among the most prevalent comorbidities and were associated with greater functional impairment and reduced quality of life. Bipolar disorder presented important diagnostic challenges due to overlapping symptoms, while substance use disorders were associated with poorer psychosocial outcomes and increased treatment complexity. Sleep disorders were highly prevalent and appeared to interact bidirectionally with ADHD symptoms. The frequent co-occurrence of ADHD and autism spectrum disorder further supports shared neurodevelopmental mechanisms. Emotional dysregulation and executive dysfunction emerged as potential transdiagnostic factors contributing to psychiatric vulnerability. Conclusions: Adult ADHD should be considered a complex, multidimensional disorder that rarely occurs in isolation. Comprehensive assessment of psychiatric comorbidity and integrated, individualized treatment are essential to improve clinical outcomes and quality of life.
- Open Access
- 24 September 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 5 (3(51))
THE IMPACT OF DEPRESSION ON SEMEN QUALITY
Objective: Depression is characterized by low or depressed mood, anhedonia, feelings of guilt or worthlessness, lack of energy, fatigue, appetite changes, psychomotor retardation, sleep disturbances, or suicidal thoughts. Despite numerous studies analyzing the epidemiology, symptomatology, and treatment of depression, the impact on men’s reproductive health, semen quality, and procreation requires further research. This review aims to summarize the current state of knowledge about the impact of depression on semen parameters and quality. Methods: PubMed, ScienceDirect, and Google Scholar were systematically searched for studies. The search included original articles published from January 2017 to December 2026. Only studies in English and with full-text access were considered. Inclusion criteria focused on original research assessing depressive disorder, semen quality, and semen analysis. Data were extracted and synthesized narratively. Key Findings: Depression significantly affects semen parameters and quality, causing a reduction in sperm motility, sperm density, and sperm concentration. Conclusion: Depression has an impact on semen quality and reproductive health. This review highlights the importance of recognizing and addressing sexual dysfunction alongside psychological symptoms, as well as the need for a multidisciplinary approach to the management of depression. In the end, Further research and deeper investigation are necessary to fully examine the complex impacts of depression on semen quality, even though these collective studies demonstrate a strong correlation between mental health and fertility.
- 24 September 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 5 (3(51))
Open AccessTHE IMPACT OF DEPRESSION ON SEMEN QUALITY
Objective: Depression is characterized by low or depressed mood, anhedonia, feelings of guilt or worthlessness, lack of energy, fatigue, appetite changes, psychomotor retardation, sleep disturbances, or suicidal thoughts. Despite numerous studies analyzing the epidemiology, symptomatology, and treatment of depression, the impact on men’s reproductive health, semen quality, and procreation requires further research. This review aims to summarize the current state of knowledge about the impact of depression on semen parameters and quality. Methods: PubMed, ScienceDirect, and Google Scholar were systematically searched for studies. The search included original articles published from January 2017 to December 2026. Only studies in English and with full-text access were considered. Inclusion criteria focused on original research assessing depressive disorder, semen quality, and semen analysis. Data were extracted and synthesized narratively. Key Findings: Depression significantly affects semen parameters and quality, causing a reduction in sperm motility, sperm density, and sperm concentration. Conclusion: Depression has an impact on semen quality and reproductive health. This review highlights the importance of recognizing and addressing sexual dysfunction alongside psychological symptoms, as well as the need for a multidisciplinary approach to the management of depression. In the end, Further research and deeper investigation are necessary to fully examine the complex impacts of depression on semen quality, even though these collective studies demonstrate a strong correlation between mental health and fertility.
- Open Access
- 10 September 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 71, 74800
Alternate-Day, Low-Dose Oral Iron Supplementation and Hepcidin-Guided Dosing Timing in Athletes: A Narrative Review
Introduction: Iron deficiency is one of the most common micronutrient deficiencies in athletes, particularly in endurance athletes and women. The effectiveness of oral iron supplementation depends not only on the dose but also on supplementation timing, dosing frequency, and hepcidin regulation. Aim: To summarize current evidence on oral iron supplementation strategies in athletes, with particular emphasis on the role of hepcidin in optimizing iron absorption. Material and methods: A literature search was conducted through PubMed (MEDLINE) and Google Scholar. Randomized controlled trials, stable-isotope studies, and review articles published in English up to February 2026 were analyzed. Results: Current evidence suggests that alternate-day, low-dose oral iron supplementation improves gastrointestinal tolerance and may enhance iron absorption compared with daily dosing. Iron absorption is influenced by circadian rhythm and exercise-induced increases in hepcidin, making supplementation timing clinically important. Conventional ferrous salts remain the first-line treatment, whereas novel formulations and intravenous iron may be appropriate in selected cases. Conclusions: Iron supplementation should be individualized according to iron status, training schedule, treatment tolerance, and clinical needs. Optimizing dosing frequency and timing represents a simple strategy to improve treatment effectiveness. Further athlete-specific studies are needed to establish evidence-based recommendations.
- 10 September 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 71, 74800
Open AccessAlternate-Day, Low-Dose Oral Iron Supplementation and Hepcidin-Guided Dosing Timing in Athletes: A Narrative Review
Introduction: Iron deficiency is one of the most common micronutrient deficiencies in athletes, particularly in endurance athletes and women. The effectiveness of oral iron supplementation depends not only on the dose but also on supplementation timing, dosing frequency, and hepcidin regulation. Aim: To summarize current evidence on oral iron supplementation strategies in athletes, with particular emphasis on the role of hepcidin in optimizing iron absorption. Material and methods: A literature search was conducted through PubMed (MEDLINE) and Google Scholar. Randomized controlled trials, stable-isotope studies, and review articles published in English up to February 2026 were analyzed. Results: Current evidence suggests that alternate-day, low-dose oral iron supplementation improves gastrointestinal tolerance and may enhance iron absorption compared with daily dosing. Iron absorption is influenced by circadian rhythm and exercise-induced increases in hepcidin, making supplementation timing clinically important. Conventional ferrous salts remain the first-line treatment, whereas novel formulations and intravenous iron may be appropriate in selected cases. Conclusions: Iron supplementation should be individualized according to iron status, training schedule, treatment tolerance, and clinical needs. Optimizing dosing frequency and timing represents a simple strategy to improve treatment effectiveness. Further athlete-specific studies are needed to establish evidence-based recommendations.
- Open Access
- 8 August 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 66, 74082
Pulmonary embolism in pregnancy and the postpartum period – a literature review
Background: Pulmonary embolism (PE) is a leading cause of maternal morbidity and mortality worldwide. Pregnancy and the postpartum period increase the risk of venous thromboembolism due to hypercoagulability, venous stasis, and endothelial injury. Diagnosis remains challenging because symptoms often overlap with physiological changes in pregnancy, delaying recognition and increasing the risk of adverse outcomes. Aim: To review current evidence on the epidemiology, risk factors, pathophysiology, clinical presentation, diagnosis, and management of pulmonary embolism during pregnancy. Material and methods: A narrative literature review was conducted using publications from PubMed and Scopus, including original studies, systematic reviews, and meta-analyses on pulmonary embolism during pregnancy and the postpartum period. Results: Pulmonary embolism in pregnancy presents significant diagnostic challenges due to nonspecific symptoms and physiological changes affecting clinical assessment. Pregnancy-adapted diagnostic algorithms combining clinical pre-test probability with D-dimer testing may improve diagnostic accuracy while reducing unnecessary imaging. When imaging is required, computed tomography pulmonary angiography and ventilation–perfusion scanning provide high diagnostic performance with acceptable safety. Management is based on risk stratification. Low-molecular-weight heparin is the first-line treatment for hemodynamically stable patients, whereas reperfusion therapies are reserved for high-risk cases. Conclusions: Pulmonary embolism remains a serious pregnancy complication requiring early diagnosis and prompt treatment. Advances in diagnostic strategies and management have improved patient care; however, further studies are needed to optimize risk assessment and treatment in this population.
- 8 August 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 66, 74082
Open AccessPulmonary embolism in pregnancy and the postpartum period – a literature review
Background: Pulmonary embolism (PE) is a leading cause of maternal morbidity and mortality worldwide. Pregnancy and the postpartum period increase the risk of venous thromboembolism due to hypercoagulability, venous stasis, and endothelial injury. Diagnosis remains challenging because symptoms often overlap with physiological changes in pregnancy, delaying recognition and increasing the risk of adverse outcomes. Aim: To review current evidence on the epidemiology, risk factors, pathophysiology, clinical presentation, diagnosis, and management of pulmonary embolism during pregnancy. Material and methods: A narrative literature review was conducted using publications from PubMed and Scopus, including original studies, systematic reviews, and meta-analyses on pulmonary embolism during pregnancy and the postpartum period. Results: Pulmonary embolism in pregnancy presents significant diagnostic challenges due to nonspecific symptoms and physiological changes affecting clinical assessment. Pregnancy-adapted diagnostic algorithms combining clinical pre-test probability with D-dimer testing may improve diagnostic accuracy while reducing unnecessary imaging. When imaging is required, computed tomography pulmonary angiography and ventilation–perfusion scanning provide high diagnostic performance with acceptable safety. Management is based on risk stratification. Low-molecular-weight heparin is the first-line treatment for hemodynamically stable patients, whereas reperfusion therapies are reserved for high-risk cases. Conclusions: Pulmonary embolism remains a serious pregnancy complication requiring early diagnosis and prompt treatment. Advances in diagnostic strategies and management have improved patient care; however, further studies are needed to optimize risk assessment and treatment in this population.
- Open Access
- 17 July 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Journal of Education, Health and Sport
- Vol. 94, 73071
Psychedelic Therapies in the Management of Post-Traumatic Stress Disorder
Background. Post-Traumatic Stress Disorder (PTSD) is an important public health challenge typically treated with trauma-focused psychotherapy and Selective Serotonin Reuptake Inhibitors (SSRIs). However, high rates of residual symptoms associated with these standard treatments have led to a renewed interest in psychedelic-assisted therapies. Aim. This review attempts to examine emerging psychedelic therapies in the management of PTSD, with a primary focus on 3,4-methylenedioxymethamphetamine (MDMA), psilocybin, and ketamine. Material and methods. A literature search was carried out using PubMed, Google Scholar, and Scopus to identify relevant studies using keywords such as 'PTSD', 'MDMA', 'psychedelics', 'ketamine', 'psychedelic-assisted therapy', 'neuroplasticity', and 'fear extinction'. Results. Psychedelics induce neuroplasticity and augment fear extinction, primarily through the AMPAR-BDNF-TrkB-mTOR pathway and 5-HT2A receptors. MDMA-assisted therapy demonstrates high efficacy, with a trial showing that 67% of participants no longer met PTSD criteria at the study endpoint. Psilocybin effectively treats common comorbidities like anxiety and treatment-resistant depression. Ketamine offers rapid symptom alleviation, making it notably beneficial for treatment-resistant cases with a high risk of self-harm and suicide. Conclusions. Psychedelic therapies, particularly MDMA-assisted therapy, represent a potential breakthrough by targeting the underlying causes of PTSD rather than merely suppressing symptoms. In spite of current regulatory problems, they hold meaningful promise, pointing out the need for standardized treatment protocols to ensure safety and reproducibility in future research.
- 17 July 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Journal of Education, Health and Sport
- Vol. 94, 73071
Open AccessPsychedelic Therapies in the Management of Post-Traumatic Stress Disorder
Background. Post-Traumatic Stress Disorder (PTSD) is an important public health challenge typically treated with trauma-focused psychotherapy and Selective Serotonin Reuptake Inhibitors (SSRIs). However, high rates of residual symptoms associated with these standard treatments have led to a renewed interest in psychedelic-assisted therapies. Aim. This review attempts to examine emerging psychedelic therapies in the management of PTSD, with a primary focus on 3,4-methylenedioxymethamphetamine (MDMA), psilocybin, and ketamine. Material and methods. A literature search was carried out using PubMed, Google Scholar, and Scopus to identify relevant studies using keywords such as 'PTSD', 'MDMA', 'psychedelics', 'ketamine', 'psychedelic-assisted therapy', 'neuroplasticity', and 'fear extinction'. Results. Psychedelics induce neuroplasticity and augment fear extinction, primarily through the AMPAR-BDNF-TrkB-mTOR pathway and 5-HT2A receptors. MDMA-assisted therapy demonstrates high efficacy, with a trial showing that 67% of participants no longer met PTSD criteria at the study endpoint. Psilocybin effectively treats common comorbidities like anxiety and treatment-resistant depression. Ketamine offers rapid symptom alleviation, making it notably beneficial for treatment-resistant cases with a high risk of self-harm and suicide. Conclusions. Psychedelic therapies, particularly MDMA-assisted therapy, represent a potential breakthrough by targeting the underlying causes of PTSD rather than merely suppressing symptoms. In spite of current regulatory problems, they hold meaningful promise, pointing out the need for standardized treatment protocols to ensure safety and reproducibility in future research.